Stock PRO SOCIETE DE PROMOTION PHARMACEUTIQUE DU MAGHREB S.A.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Societe de Promotion Pharmaceutique du Maghreb S.A.

Equities

PRO

MA0000011660

Pharmaceuticals

End-of-day quote Casablanca S.E.
Other stock markets
 06:00:00 2024-05-30 pm EDT 		5-day change 1st Jan Change
984 MAD +5.35% Intraday chart for Societe de Promotion Pharmaceutique du Maghreb S.A. +5.35% -1.60%
Apr. 30 Societe de Promotion Pharmaceutique du Maghreb S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 Societe de Promotion Pharmaceutique du Maghreb S.A. Reports Earnings Results for the Half Year Ended June 30, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 1,000 856 710 1,140 1,068 1,000
Enterprise Value (EV) 1 1,022 707.7 570.9 934.9 1,011 1,068
P/E ratio 25.8 x 16.4 x 11.8 x 16.5 x 14.2 x 17.6 x
Yield - - - 3.51% 3.75% -
Capitalization / Revenue 2.25 x 1.64 x 1.24 x 1.81 x 1.52 x 1.24 x
EV / Revenue 2.3 x 1.35 x 1 x 1.48 x 1.44 x 1.33 x
EV / EBITDA - - - - - 10,614,080 x
EV / FCF - - - - -8,263,604 x -9,737,452 x
FCF Yield - - - - -0% -0%
Price to Book 3.67 x 2.64 x 1.85 x 2.69 x 2.33 x 2.07 x
Nbr of stocks (in thousands) 1,000 1,000 1,000 1,000 1,000 1,000
Reference price 2 1,000 856.0 710.0 1,140 1,068 1,000
Announcement Date 3/26/19 3/30/20 4/15/21 4/26/22 4/25/23 4/30/24
1MAD in Million2MAD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 444.5 522.5 573.2 630.5 704.6 805.5
EBITDA - - - - - 100.7
EBIT 1 54.72 91.24 101.5 104.9 134.1 88.65
Operating Margin 12.31% 17.46% 17.7% 16.64% 19.03% 11%
Earnings before Tax (EBT) 1 55.04 81.58 90.45 102.7 114.3 87.79
Net income 1 38.75 52.11 60.26 68.97 75.28 56.9
Net margin 8.72% 9.97% 10.51% 10.94% 10.68% 7.06%
EPS 2 38.75 52.11 60.26 68.97 75.28 56.90
Free Cash Flow - - - - -122.4 -109.7
FCF margin - - - - -17.37% -13.62%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - 40.00 40.00 -
Announcement Date 3/26/19 3/30/20 4/15/21 4/26/22 4/25/23 4/30/24
1MAD in Million2MAD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 22.4 - - - - 68.4
Net Cash position 1 - 148 139 205 56.8 -
Leverage (Debt/EBITDA) - - - - - 0.6798 x
Free Cash Flow - - - - -122 -110
ROE (net income / shareholders' equity) 15.3% 17.5% 17% 17.1% 17.1% 12.1%
ROA (Net income/ Total Assets) 7.36% 11.7% 12.3% 11.3% 12.2% 6.34%
Assets 1 526.2 444.1 491.8 610.7 619.3 897.3
Book Value Per Share 2 272.0 324.0 385.0 424.0 459.0 484.0
Cash Flow per Share 2 26.60 119.0 104.0 160.0 106.0 62.70
Capex - - - - 129 118
Capex / Sales - - - - 18.29% 14.63%
Announcement Date 3/26/19 3/30/20 4/15/21 4/26/22 4/25/23 4/30/24
1MAD in Million2MAD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Generic Pharmaceuticals

1st Jan change Capi.
SOCIETE DE PROMOTION PHARMACEUTIQUE DU MAGHREB S.A. Stock Societe de Promotion Pharmaceutique du Maghreb S.A.
-1.60% 98.92M
SUN PHARMACEUTICAL INDUSTRIES LTD. Stock Sun Pharmaceutical Industries Ltd.
+15.91% 41.97B
OTSUKA HOLDINGS CO., LTD. Stock Otsuka Holdings Co., Ltd.
+22.40% 22.34B
SANDOZ GROUP AG Stock Sandoz Group AG
+18.48% 15.25B
CIPLA LIMITED Stock Cipla Limited
+16.12% 14B
ZYDUS LIFESCIENCES LIMITED Stock Zydus Lifesciences Limited
+45.12% 12.06B
ONO PHARMACEUTICAL CO., LTD. Stock Ono Pharmaceutical Co., Ltd.
-9.58% 6.8B
THE MEDICINES COMPANY Stock The Medicines Company
-0.05% 6.79B
STADA ARZNEIMITTEL Stock STADA Arzneimittel
-8.87% 5.73B
ASPEN PHARMACARE HOLDINGS LIMITED Stock Aspen Pharmacare Holdings Limited
+14.18% 5.49B
Generic Pharmaceuticals
  1. Stock Market
  2. Equities
  3. PRO Stock
  4. Financials Societe de Promotion Pharmaceutique du Maghreb S.A.